Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2− bone-only metastatic breast cancer

Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors plus endocrine therapy (ET) are more effective than ET alone in diverse populations of patients with HR+/HER2− metastatic breast cancer (MBC). However, real-world effectiveness data for CDK4/6 inhibitors plus ET combination in bone-only MBC ar...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Adam Brufsky, Rachel M. Layman, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B. Cohen, Melissa Estevez, Paul Cottu, Giuseppe Curigliano, Hope S. Rugo
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2026-04-01
Rangatū:	Breast
Ngā marau:	Bone metastasis Cyclin-dependent kinases Metastatic breast cancer HR+/HER2− Palbociclib Real-world
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S0960977626000548
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!